Indeed, Zitvogel et al. have showed that DCexos from tumor-associated antigens (TAAs)–stimulated DCs prime tumor-specific CD8 T cell responses in vivo, and a single intradermal injection of DCexos achieved better anti-tumor efficacy in eradicating established tumors compared to the injection of DCs [60]. This evidence concerns the gene CD8A and neoplasm.